# US 8,038,994 B2 · Combination therapy for treating disease > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,038,994 B2 - Document ID: US8038994B2 - Status: Granted - Kind: B2 - Application number: 10/831,886 - Filed: 2004-04-26 - Published: 2005-03-24 - Granted: 2011-10-18 - Earliest claimed: 2001-05-31 - Assignees: Quest Pharmatech Inc. - Inventors: Birgit C. Schultes; Christopher F. Nicodemus; Antoine A. Noujaim; Ragupathy Madiyalakan - Web page: https://patentgrep.com/patent/US8038994B2 ## CPC - C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate} - A61K 39/39558: {against tumor tissues, cells, antigens} - A61K 2039/505: {comprising antibodies} - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen. ## Claims ### Claim 1 A method for treating cancer, comprising administering to a patient suffering from cancer a chemotherapeutic drug, and a composition comprising an unlabeled xenotypic monoclonal antibody specific for a multi-epitopic in vivo antigen present in the patient's serum, wherein the multi-epitopic in vivo antigen is MUC-1, CA 1251, prostate specific antigen, CA 19.9, or TAG-72, wherein the chemotherapeutic drug is administered within a week of administering the composition. ### Claim 2 (depends on 1) The method of claim 1, wherein the xenotypic monoclonal antibody is murine. ### Claim 3 (depends on 2) The method of claim 2, wherein the xenotypic monoclonal antibody is selected from the group consisting of: Alt-1 which is producible by a hybridoma having ATCC deposit number PTA-975, Alt-2 which is producible by a hybridoma having ATCC deposit number PTA-1883, Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2692, Alt-5 which is producible by a hybridoma having ATCC deposit number PTA-2690, and Alt-6 which is producible by a hybridoma having ATCC deposit number HB 12526. ### Claim 4 (depends on 1) The method of claim 1, wherein the patient is a human. ### Claim 5 (depends on 1, 3) The method of claim 1 or 3, wherein the xenotypic monoclonal antibody in the composition is administered in a dose of less than or equal to 2 mg. ### Claim 6 (depends on 2) The method of claim 2, further comprising surgically removing the cancer. ### Claim 7 A method for treating cancer, comprising: (1) surgically removing the cancer, and (2) administering: (a) a composition comprising an unlabeled xenotypic monoclonal antibody specific for a multi-epitopic in vivo antigen present in the patient's serum, said xenotypic monoclonal antibody is in a dose equal to or less than 2 mg, and, (b) a chemotherapeutic drug, wherein the chemotherapeutic drug is administered within a week of administering the composition. ### Claim 8 (depends on 7) The method of claim 7, wherein the xenotypic monoclonal antibody is selected from the group consisting of: Alt-1 which is producible by a hybridoma having ATCC deposit number PTA-975, Alt-2 which is producible by a hybridoma having ATCC deposit number PTA-1883, Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2692, Alt-5 which is producible by a hybridoma having ATCC deposit number PTA-2690, and Alt-6 which is producible by a hybridoma having ATCC deposit number HB 12526. ### Claim 9 (depends on 7) The method of claim 7, wherein administration of the composition comprises a 20 minute intravenous infusion. ### Claim 10 A method for treating cancer in a patient, comprising: (1) surgically removing the cancer, and (2) administering a composition comprising an unlabeled xenotypic monoclonal antibody at weeks 1, 3, 5, 7 and 9, followed by concurrently administering a chemotherapeutic drug and the composition, said xenotypic monoclonal antibody in the composition is administered in a dose less than or equal to 2 mg at week 12. ### Claim 11 (depends on 9) The method of claim 9, wherein the xenotypic monoclonal antibody is selected from the group consisting of: Alt-1 which is producible by a hybridoma having ATCC deposit number PTA-975, Alt-2 which is producible by a hybridoma having ATCC deposit number PTA-1883, Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2692, Alt-5 which is producible by a hybridoma having ATCC deposit number PTA-2690, and Alt-6 which is producible by a hybridoma having ATCC deposit number HB 12526. ### Claim 12 A method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen comprising administering to the patient a chemotherapeutic drug and a composition comprising an unlabeled monoclonal antibody or a fragment thereof that specifically binds to a first epitope on the antigen and allowing the monoclonal antibody or fragment thereof to form a monoclonal antibody or fragment thereof / antigen pair, wherein a host immune response is elicited against a second epitope on the antigen, wherein antigen is selected from the group consisting of MUC-1, CA 125, prostate specific antigen, CA 19.9 or TAG-72, wherein said antigen does not elicit an effective host immune response, wherein the chemotherapeutic drug is administered within a week of administering the monoclonal antibody and wherein the monoclonal antibody is selected from the group consisting of: Alt-1 which is producible by a hybridoma having ATCC deposit number PTA-975, Alt-2 which is producible by a hybridoma having ATCC deposit number PTA-1883, Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2692, Alt-5 which is producible by a hybridoma having ATCC deposit number PTA-2690, and Alt-6 which is producible by a hybridoma having ATCC deposit number RB 12526. ### Claim 13 (depends on 12) The method of claim 12, wherein the monoclonal antibody is a murine xenotypic monoclonal antibody. ### Claim 14 (depends on 12) The method of claim 12, wherein the patient is human. ### Claim 15 (depends on 12) The method of claim 12, wherein the antibody is administered in a dose of equal to or less than 2 mg. ### Claim 16 (depends on 12) The method of claim 12, further comprising surgically removing the cancer. ### Claim 17 A method for treating cancer, comprising administering a chemotherapeutic drug, an antigen, and a monoclonal antibody or a fragment thereof that binds the antigen, wherein the chemotherapeutic drug is administered within a week of administering the monoclonal antibody and wherein the monoclonal antibody is selected from the group consisting of: Alt-1 which is producible by a hybridoma having ATCC deposit number PTA-975, Alt-2 which is producible by a hybridoma having ATCC deposit number PTA-1883, Alt-3 which is producible by a hybridoma having ATCC deposit number PTA-2691, Alt-4 which is producible by a hybridoma having ATCC deposit number PTA-2692, Alt-5 which is producible by a hybridoma having ATCC deposit number PTA-2690, and Alt-6 which is producible by a hybridoma having ATCC deposit number HB 12526. ### Claim 18 (depends on 17) The method of claim 17, wherein the patient is human. ### Claim 19 (depends on 17) The method of claim 17, wherein the antibody is administered in a dose of equal to or less than 2 mg. ### Claim 20 (depends on 17) The method of claim 17, wherein the monoclonal antibody is a murine monoclonal antibody.